CYC

CYCLOPHARM FPO [CYC]
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.
Healthcare · ASX Small Cap
$0.5100 +0.0%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-03-04
Get alerts when CYC triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track CYC — Free

Active Signals

Bullish Signals

  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Low cash runway (3 quarters) - dilution risk
  • Low P/S ratio (1.9x)
  • Moderate revenue growth (+14%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (7% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (25%)
  • Sentiment is mixed — no strong consensus either way
  • Beneish M-Score -0.29 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)
  • Calendar: Clinical Trial in 6d (+5pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-53%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.63%/day)

Expected next for CYC

15 Sep 2026Clinical Trial UpdateCompany-indicated window
Window: 1 Jul to 31 Dec
From a company announcement on 25 Feb 2026
The last 1 moved CYC +1.5% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE Cyclopharm 1H 2026 Results Webinar
NONE CYC 1H2026 Results Summary
NONE Half Yearly Report and Accounts

Recent ASX Announcements

2026-08-23 Cyclopharm 1H 2026 Results Webinar
2026-08-23 CYC 1H2026 Results Summary PRICE SENSITIVE
2026-08-23 Half Yearly Report and Accounts PRICE SENSITIVE
2026-07-28 New US Lung Imaging Guidelines Name Technegas as Preferred A PRICE SENSITIVE
2026-07-27 ausbiz TV Presentation

Key Metrics

$64.1M
Market Cap
56K
Avg Volume
1.3x
Vol Ratio
$0.45 — $1.29
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-53.9%
ROE
-53.2%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 51%
LLeader vs LaggardlaggardRS: -5
IInstitutional SponsorshippassInst: 25%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:CYC vs NUZCYC vs IPDCYC vs HIQ
Share this analysis

Track CYC and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required